U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184697) titled 'Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD.' on Sept. 04.
Brief Summary: This is a single-center, randomized, double-blind, sham-controlled, crossover exploratory clinical trial designed to evaluate the therapeutic effects of task-specific, biomarker-driven HD-ctACS on treatment-resistant depression (TRD). The study will enroll 10 patients diagnosed with TRD. Each participant will, in a randomized order, undergo a 4-week active HD-ctACS treatment period and a 4-week sham stimulation (delayed HD-ctACS) period, separated by an 8-week washout period. The primary objective is to assess the efficacy of HD-ctA...